HIV-positive TB patients on ART (antiretroviral therapy) in Paraguay
Paraguay: HIV-positive TB patients on ART (antiretroviral therapy) was 36.0% in 2024. ▲ Rising
HIV-positive TB patients on ART (antiretroviral therapy) in Paraguay, 2008–2024
Source: World Health Organization, Global Health Observatory.
Analysis
Paraguay recorded 36.0% for hiv-positive tb patients on art (antiretroviral therapy) in 2024. That is the lowest value across all 17 years on record.
Compared with earlier readings it is down 56.1% on the previous year and down 58.6% over ten years.
Over the whole period, hiv-positive tb patients on art (antiretroviral therapy) in Paraguay peaked at 100.0% in 2019 and was at its lowest, 36.0%, in 2024.
Paraguay ranks 143rd of 144 countries on this measure, in the bottom quarter.
The long-run direction has been consistently rising across the 17 years of available data.
HIV-positive TB patients on ART (antiretroviral therapy) in Paraguay, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 66.0% | — |
| 2009 | 51.0% | -22.7% |
| 2010 | 67.0% | +31.4% |
| 2011 | 56.0% | -16.4% |
| 2012 | 79.0% | +41.1% |
| 2013 | 67.0% | -15.2% |
| 2014 | 87.0% | +29.9% |
| 2015 | 83.0% | -4.6% |
| 2016 | 76.0% | -8.4% |
| 2017 | 88.0% | +15.8% |
| 2018 | 91.0% | +3.4% |
| 2019 | 100.0% | +9.9% |
| 2020 | 90.0% | -10.0% |
| 2021 | 87.0% | -3.3% |
| 2022 | 92.0% | +5.7% |
| 2023 | 82.0% | -10.9% |
| 2024 | 36.0% | -56.1% |
Paraguay compared with similar countries
- Paraguay's 36.0% is below the median for upper middle income countries, which is 93.0%, 39% of the median. (48 countries reporting)
- Paraguay's 36.0% is below the median for Latin America & Caribbean, which is 83.0%, 43% of the median. (31 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 58.5% | 51.0% | 66.0% | 2 |
| 2010s | 79.4% | 56.0% | 100.0% | 10 |
| 2020s | 77.4% | 36.0% | 92.0% | 5 |
Countries ranked near Paraguay
More health data for Paraguay
- Un projection of annual infant deaths, annual growth rate -2.02 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.2374 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,098 deaths per 1,000 people (2090)
- Number of infants who die before age 1 339 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -0.5252 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0469 units per person (2025)
- Population ages 00-04, male, annual growth rate -0.5185 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is hiv-positive tb patients on art (antiretroviral therapy) in Paraguay?
- Hiv-positive tb patients on art (antiretroviral therapy) in Paraguay was 36.0% in 2024, according to World Health Organization, Global Health Observatory.
- What is the highest hiv-positive tb patients on art (antiretroviral therapy) recorded in Paraguay?
- The highest recorded value was 100.0% in 2019.
- What is the lowest hiv-positive tb patients on art (antiretroviral therapy) recorded in Paraguay?
- The lowest recorded value was 36.0% in 2024.
- How does Paraguay rank for hiv-positive tb patients on art (antiretroviral therapy)?
- Paraguay ranks 143rd out of 144 countries with data for 2024.
- Is hiv-positive tb patients on art (antiretroviral therapy) rising or falling in Paraguay?
- Over the last ten years it is down 58.6%. The long-run trend across the full record is rising.
- Where does this Paraguay data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 17 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).